NANCY DENYES - 03 Feb 2025 Form 4 Insider Report for aTYR PHARMA INC (ATYR)

Role
General Counsel
Signature
/s/ Nancy E. Denyes
Issuer symbol
ATYR
Transactions as of
03 Feb 2025
Net transactions value
-$3,398
Form type
4
Filing time
04 Feb 2025, 18:11:20 UTC
Previous filing
10 Jan 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ATYR Common Stock Options Exercise +2,687 +11% 27,454 03 Feb 2025 Direct F1, F2, F3
transaction ATYR Common Stock Sale $3,398 -899 -3.3% $3.78 26,555 04 Feb 2025 Direct F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ATYR Restricted Stock Unit Options Exercise $0 -2,687 -50% $0.000000 2,687 03 Feb 2025 Common Stock 2,687 Direct F2, F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents shares acquired upon the vesting of restricted stock units (RSUs) granted to the Reporting Person on February 3, 2022.
F2 Restricted stock units convert into common stock on a one-for-one basis.
F3 Includes 2,500 shares acquired on November 15, 2024 under the Company's 2015 Employee Purchase Plan.
F4 Sale made by the Reporting Person to satisfy tax withholding obligations in connection with the partial vesting of RSUs granted on February 3, 2022.
F5 The RSUs vest in four equal annual installments beginning on February 3, 2023, such that the RSUs will fully vest on February 3, 2026. The RSUs are subject to accelerated vesting upon termination without cause upon a change of control of the Issuer.